Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNABW) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for Ginkgo Bioworks Holdings (DNABW) over the last 3 years, with Q2 2024 value amounting to $47.9 million.

  • Ginkgo Bioworks Holdings' Asset Writedowns and Impairment rose 43169.65% to $47.9 million in Q2 2024 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 7013.75%. This contributed to the annual value of $4.8 million for FY2024, which is 9602.73% down from last year.
  • According to the latest figures from Q2 2024, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment is $47.9 million, which was up 43169.65% from $112.4 million recorded in Q3 2023.
  • In the past 5 years, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment registered a high of $112.4 million during Q3 2023, and its lowest value of -$10.1 million during Q4 2022.
  • For the 3-year period, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment averaged around $39.8 million, with its median value being $28.4 million (2023).
  • Over the last 5 years, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment had its largest YoY gain of 43169.65% in 2024, and its largest YoY loss of 43169.65% in 2024.
  • Over the past 3 years, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment (Quarter) stood at -$10.1 million in 2022, then surged by 1212.9% to $112.4 million in 2023, then plummeted by 57.42% to $47.9 million in 2024.
  • Its Asset Writedowns and Impairment was $47.9 million in Q2 2024, compared to $112.4 million in Q3 2023 and $9.0 million in Q2 2023.